COCP

Cocrystal Pharma Inc

Add to Watchlist

Advanced Chart

1.670

-0.069(-3.967%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.750

Open

1.7223

VWAP

Vol

25.99K

Mkt Cap

16.99M

Low

1.650

Amount

EV/EBITDA(TTM)

Total Shares

10.17M

10.77M

EV/OCF(TTM)

P/S(TTM)

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

-0.300

-43.4%

-0.287

-41.5%

-0.257

-19.79%

Estimates Revision

The market is revising No Change the revenue expectations for Cocrystal Pharma, Inc. (COCP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 10.59%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+25.1%

In Past 3 Month

Stock Price

Go Up

+10.59%

In Past 3 Month

2 Analyst Rating

379.07% Upside

Wall Street analysts forecast COCP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COCP is 8.00 USD with a low forecast of 6.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

379.07% Upside

Current: 1.670

Low

6.00

Averages

8.00

High

10.00

379.07% Upside

Current: 1.670

Low

6.00

Averages

8.00

High

10.00

H.C. Wainwright

Buy

downgrade

$7 -> $6

2025-06-21

Reason

H.C. Wainwright

Price Target

$7 -> $6

2025-06-21

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Cocrystal Pharma to $6 from $7 and keeps a Buy rating on the shares. The firm says CDI-988 demonstrated "further promise" via activity against emergent norovirus variants. It cites anticipated equity dilution for the target cut.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2025-01-22

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-01-22

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Maintains

$10 → $7

2024-08-22

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$10 → $7

2024-08-22

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cocrystal Pharma Inc (COCP.O) is -1.57, compared to its 5-year average forward P/E of -3.10. For a more detailed relative valuation and DCF analysis to assess Cocrystal Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.10

Current PE

-1.57

Overvalued PE

0.21

Undervalued PE

-6.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.17

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.52

Undervalued EV/EBITDA

-0.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

19.46

Current PS

0.00

Overvalued PS

44.11

Undervalued PS

-5.20

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

-43.70%

-2.34M

Operating Profit

FY2025Q1

YoY :

-41.84%

-2.30M

Net Income after Tax

FY2025Q1

YoY :

-41.03%

-0.23

EPS - Diluted

FY2025Q1

YoY :

-37.38%

-2.83M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

COCP News & Events

Events Timeline

2025-05-29 (ET)

2025-05-29

08:08:57

Cocrystal announces CC-42344 active against 204 Texas H5N1 avian influenza

2025-05-15 (ET)

2025-05-15

08:02:19

Cocrystal Pharma reports Q1 EPS (23c) vs (39c) last year

2025-04-24 (ET)

2025-04-24

08:19:54

Cocrystal Pharma's norovirus oral candidate demonstrates 'potent activity'

News

9.0

05-29Newsfilter

Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain

9.5

05-15Newsfilter

Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

9.0

04-24Newsfilter

Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants